WO2006089298A3 - Pyrimidine-fused diazepine derivatives and indole-fused pteridines - Google Patents

Pyrimidine-fused diazepine derivatives and indole-fused pteridines Download PDF

Info

Publication number
WO2006089298A3
WO2006089298A3 PCT/US2006/006303 US2006006303W WO2006089298A3 WO 2006089298 A3 WO2006089298 A3 WO 2006089298A3 US 2006006303 W US2006006303 W US 2006006303W WO 2006089298 A3 WO2006089298 A3 WO 2006089298A3
Authority
WO
WIPO (PCT)
Prior art keywords
fused
indole
pyrimidine
pteridines
diazepine derivatives
Prior art date
Application number
PCT/US2006/006303
Other languages
French (fr)
Other versions
WO2006089298A2 (en
Inventor
Xu Bai Bai
Qun Dang
Robert J Ternansky Ternansky
Original Assignee
Attenuon Llc
Changchun Discovery Sciences L
Xu Bai Bai
Qun Dang
Robert J Ternansky Ternansky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc, Changchun Discovery Sciences L, Xu Bai Bai, Qun Dang, Robert J Ternansky Ternansky filed Critical Attenuon Llc
Priority to EP06748243A priority Critical patent/EP1848506A2/en
Publication of WO2006089298A2 publication Critical patent/WO2006089298A2/en
Publication of WO2006089298A3 publication Critical patent/WO2006089298A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to pyrimidine-fused benzodiazepine derivative and indole-fused pteridine compounds. The invention further relates to libraries containing two or more of such compounds and methods of making such compounds. The invention also relates to methods of screening for bioactive pyrimidine-fused benzodiazepine derivative and indole-fused pteridine compounds.
PCT/US2006/006303 2005-02-18 2006-02-21 Pyrimidine-fused diazepine derivatives and indole-fused pteridines WO2006089298A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06748243A EP1848506A2 (en) 2005-02-18 2006-02-21 Pyrimidine-fused diazepine derivatives and indole-fused pteridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65460605P 2005-02-18 2005-02-18
US60/654,606 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006089298A2 WO2006089298A2 (en) 2006-08-24
WO2006089298A3 true WO2006089298A3 (en) 2007-01-25

Family

ID=36917171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/006303 WO2006089298A2 (en) 2005-02-18 2006-02-21 Pyrimidine-fused diazepine derivatives and indole-fused pteridines

Country Status (3)

Country Link
EP (1) EP1848506A2 (en)
CN (1) CN101257948A (en)
WO (1) WO2006089298A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682932A1 (en) * 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomerically pure benzazepine
US8557738B2 (en) 2008-08-12 2013-10-15 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic derivative and fungicide for agricultural and horticultural use
KR101435729B1 (en) 2009-09-28 2014-09-01 닛뽕소다 가부시키가이샤 Nitrogen-containing heterocyclic compound and salt thereof, and bactericide for agricultural and horticultural use
KR102132405B1 (en) 2010-05-20 2020-07-09 어레이 바이오파마 인크. Macrocyclic compounds as trk kinase inhibitors
CN102690278B (en) * 2011-03-21 2015-07-15 长春吉大天元化学技术股份有限公司 Novel pyrimidine-fused cyclic compounds as cytokine inhibitors
CN102807574B (en) * 2011-05-30 2015-09-02 长春吉大天元化学技术股份有限公司 New pyridine sulphur nitrogen seven-membered ring derivative as antitumor drug, and its preparation method and application
CN103509024B (en) * 2012-06-28 2015-10-28 上海医药工业研究院 Kui Linpyrimido quinoline benzazepine compounds and the application as antitumor drug thereof
LT3322706T (en) 2015-07-16 2021-03-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
KR20180114057A (en) * 2016-03-04 2018-10-17 안후이 뉴 스타 파마슈티컬 디벨롭먼트 컴퍼니 리미티드 Pyrimidine 7-membered ring compound, its preparation method, its pharmaceutical composition, and its use
WO2017165300A1 (en) * 2016-03-21 2017-09-28 Regents Of The University Of Minnesota Indole and indazole compounds and therapeutic uses thereof
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
US11279707B2 (en) 2017-12-22 2022-03-22 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
JP7060694B2 (en) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Substituted pyrolo [2,3-D] pyrimidine compounds as RET kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
KR102498531B1 (en) * 2020-06-29 2023-02-13 한국과학기술연구원 Novel pyrimidodiazepin derivatives as selective protein kinase TRKC inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009384A2 (en) * 2003-07-21 2005-02-03 Imclone Systems Incorporated Egfr tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009384A2 (en) * 2003-07-21 2005-02-03 Imclone Systems Incorporated Egfr tyrosine kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FU ET AL.: "Synthesis of Novel Tricyclic Pyrimido[4,5-b][1,4]benzothiazepines via Bischler-Napieralski-Type Reactions", JOURNAL OF ORGANIC CHEMISTRY, vol. 70, no. 26, 23 December 2005 (2005-12-23), pages 10810 - 10816, XP003006644 *
YANG ET AL.: "Synthesis of Tricyclic-4-Chloro-pyrimido[4,5-b][1,4]benzodiazepines", ORGANIC LETTERS, vol. 7, no. 8, 14 April 2005 (2005-04-14), pages 1541 - 1543, XP003006645 *
ZHENG ET AL.: "Novel Heterocyclic Scaffold Consisting of Indole-Fused Pteridines", JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 7, no. 6, November 2005 (2005-11-01), pages 813 - 815, XP008075077 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Also Published As

Publication number Publication date
EP1848506A2 (en) 2007-10-31
CN101257948A (en) 2008-09-03
WO2006089298A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006089298A3 (en) Pyrimidine-fused diazepine derivatives and indole-fused pteridines
SI2395004T1 (en) Pyrrolo (2,3-b)pyridine derivatives as protein kinase inhibitors
WO2007012953A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
WO2007025540A3 (en) Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments
PL1658292T3 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
MX2010005950A (en) 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors.
ZA200710343B (en) Bicyclic derivatives as p38 kinase inhibitors
SI1966202T1 (en) HETEROARYL SUBSTITUTED PYRROLO?á2,3-B?åPYRIDINES AND PYRROLO?á2,3-B?åPYRIMIDINES AS JANUS KINASE INHIBITORS
PL1957492T3 (en) Substituted bicyclic pyrimidone derivatives
ZA200802995B (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2007044407A3 (en) Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2007044426A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
JO2778B1 (en) Certain Compounds, Compositions and Methods
WO2007146087A3 (en) SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
IL188027A0 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2007016702A3 (en) Chimeric polymerases
WO2004009596A3 (en) Pyrazolopyrimidines as kinase inhibitors
IL199378A0 (en) 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
WO2006122769A3 (en) Substituted spiro compounds and their use for producing pain-relief drugs
WO2004110990A3 (en) Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
AP2008004437A0 (en) Pyrazolo Ä4,3-DÜ pyrimidin-5-yl) derivative used as PDE5 inhibitors
HK1135688A1 (en) Pyrazolo (1,5-a)(1,3,5) triazine and pyrazolo (1,5-a) pyrimidine derivatives useful as protein kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680012920.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006748243

Country of ref document: EP